Journal article · 2024 · Open access

New treatment perspectives for negative symptoms

István Bitter

European Psychiatry, 67(S1), S17 · Published 1 April 2024 · DOI 10.1192/j.eurpsy.2024.73

Open PDFView at the publisherCite this paper

In brief

“New treatment perspectives for negative symptoms” is a 2024 journal article by István Bitter, published in European Psychiatry. OpenAlex counts 0 citations as of 20 November 2026. It is open access under a CC BY licence: the full text is free to read at European Psychiatry.

Citations
0
Authors
1

Abstract

Introduction Persistent negative symptoms of schizophrenia are generally considered difficult to treat or treatment resistant. A large number of investigational drugs developed and or tested for the treatment of persistent negative symptoms failed to show efficacy leading to pessimism in treatment and disinvestment in treatment research of negative symptoms. Objectives 1. To demonstrate, that available treatment methods – both pharmacological and non-pharmacological - are in fact effective for the treatment of negative symptoms of schizophrenia 2. To shortly summarize new drug research in this field. Method Review of research data. Results The overall estimate for the placebo effect had a medium effect size, with a Cohen’s d value of 0.6444 (SE = 0.091).1 The estimates for the placebo effect were similar in the add-on and monotherapy studies. Amisulprid was superior to placebo, cariprazine was superior to risperidone, and “direct comparisons of antipsychotics in patients with predominant negative symptoms indicated no significant difference between amisulpride and olanzapine and between asenapine and olanzapine…”2. Various nonpharmacological interventions improved negative symptoms in randomized controlled trials relative to treatment as usual (e.g. social skills training, music therapy, non-invasive brain stimulation, mindfulness, and exercise-based interventions) 3 There is a progress in research with non-dopaminergic agents for the treatment of negative symptoms (e.g. pimavanserin, roluperidon, ulotaront). Conclusions For medication classes other than antipsychotics and antidepressants, we found no reliable support for evidence-based recommendations for using these agents in the treatment of negative symptoms in clinical practice. Effect sizes for psychosocial interventions range from small to moderate. The use of placebo has shown a clinically significant positive effect on negative symptoms, a finding that warrants further research and provides a sense of optimism regarding potential therapeutic benefits. 1. Czobor, P., Kakuszi, B. and Bitter, I., 2022. Placebo response in trials of negative symptoms in schizophrenia: a critical reassessment of the evidence. Schizophrenia Bulletin, 48(6), pp.1228-1240. 2. Czobor, P., Bitter I. Pharmacologic treatment of negative symptoms: Focus on efficacy. In: Bitter I. (ed): Managing Negative Symptoms of Schizophrenia, Oxford University Press, 2020, p. 67 2. Savill, M. Psychosocial/non-pharmacologic treatment of negative symptoms: focus on efficacy. In: Bitter I. (ed): Managing Negative Symptoms of Schizophrenia, Oxford University Press, 2020, p. 87 Disclosure of Interest None Declared

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Bitter, I. (2024). New treatment perspectives for negative symptoms. European Psychiatry, 67(S1), S17. https://doi.org/10.1192/j.eurpsy.2024.73

MLA 9

Bitter, István. “New treatment perspectives for negative symptoms.” European Psychiatry, vol. 67, no. S1, 2024, p. S17. https://doi.org/10.1192/j.eurpsy.2024.73.

Chicago

Bitter, István. 2024. “New treatment perspectives for negative symptoms.” European Psychiatry 67 (S1): S17. https://doi.org/10.1192/j.eurpsy.2024.73.

Harvard

Bitter, I. (2024) ‘New treatment perspectives for negative symptoms’, European Psychiatry, 67(S1), p. S17. doi:10.1192/j.eurpsy.2024.73.

IEEE

I. Bitter, “New treatment perspectives for negative symptoms,” European Psychiatry, vol. 67, no. S1, p. S17, 2024, doi: 10.1192/j.eurpsy.2024.73.

BibTeX

@article{bitter2024treatment,
  title     = {{New treatment perspectives for negative symptoms}},
  author    = {Bitter, István},
  journal   = {European Psychiatry},
  year      = {2024},
  volume    = {67},
  number    = {S1},
  pages     = {S17},
  doi       = {10.1192/j.eurpsy.2024.73},
  url       = {https://doi.org/10.1192/j.eurpsy.2024.73}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment

  • negative symptoms
  • schizophrenia
  • treatment-resistant schizophrenia
  • antipsychotic drugs
  • amisulpride
  • cariprazine
  • risperidone
  • olanzapine

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Bitter, I. (2024). New treatment perspectives for negative symptoms. European Psychiatry, 67(S1), S17. https://doi.org/10.1192/j.eurpsy.2024.73

How many times has this paper been cited?

0 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at European Psychiatry: sign in and open the PDF from this page.

Who wrote this paper?

István Bitter.

What is the DOI of this paper?

10.1192/j.eurpsy.2024.73, permanently at https://doi.org/10.1192/j.eurpsy.2024.73. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.